News About: Pharm. Industry
Steps to boost M&As necessary
Mergers and acquisition themes sweeping global stock markets and it is no exception for the domestic pharmaceutical firms, a government official said.
He went to say that the country needs to implement a new serie...
New drug policy angers multinationals
Multinational drug manufacturers complained that their newly-invented and original drugs, which have already been undervalued in Korea, have been dealt a serious blow by the Korean government's plan to allow only cost...
Ruling of Plavix patent suit to be delayed
The controversial patent ruling of Plavix (clopidogrel bisulfate) will be made available two months later as a patent court decided to re-examine the patent's validity and enforceability.
Related parties will have ...
Dong-A's Zydena grabs bigger market share
Dong-A Pharm is expanding its share of the domestic anti-impotence drug market dominated by international drug makers.
Zydena, the first-domestically-made medication for erectile dysfunction, is challenging Viagra...
Cut-throat competition lowers prices of renowned cold remedies
The prices of such renowned cold medicines as Hituben, Hwacol and Haben were reduced to 1,200 won from 1,600 won due to more heated competition among drug makers, according to market sources.
The sources say that b...
Choong-wae Medical to break ground for new medical device plantA ground-breaking ceremony for construction of a new medical device plant was held in Choongju, Chungcheong Province on November 29.
Company officials, including Choong-wae H...
|
Dong-A gearing up to sharpen brand powerDong-A Pharm is flexing its muscles to go global with its flagship products such as anti-ulcerant Stillen and anti-impotence medicine Zydena.
Dong-A cerebrated its 75th found...
|
Janssen Korea and J&J Korea to seek co-marketing from next year
Janssen Korea and Johnson & Johnson Korea has announced that they would co-market Tylenol (acetaminophen) and Nizoral (ketoconazole) in the domestic market from January 1, next year, as part of efforts to maximize ind...
Green Cross, Abraxis BioScience enter cross licensing agreementGreen Cross Corporation and U.S.-based Abraxis BioScience Inc, an integrated and global biopharmaceutical company, announced on November 27 an agreement for the development and ...
|
Hyundai Pharm targets W300 billion won in 2010Hyundai Pharm says it will post 300 billion won in sales in 2010, said a company spokesperson.
Such a strong confidence came after the ethical sales of Levotuss (levodropropi...
|
